The medtech giant has signed a lease for a new research and development facility in San Diego, where its BD Biosciences business has long had a presence. The new real estate acquisition will serve as an expanded reagent innovation center for the segment, which develops tools and reagents for flow cytometry, single-cell multiomics, immuno-oncology and, recently, COVID-19 research.